Showing 4261-4270 of 6977 results for "".
- Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration Systemhttps://practicaldermatology.com/news/real-world-evaluation-study-confirms-benefits-of-artas-ix-robotic-hair-restoration-system/2457560/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implanta
- Pre-conditioning Added to Sebacia Microparticles Enhances Outcomeshttps://practicaldermatology.com/news/pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes/2457567/Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Mi
- Endo Presents Data on the Perception and Measurement of Cellulite Severity at ASDS Meetinghttps://practicaldermatology.com/news/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-asds-meeting/2457568/The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by
- Online Care May Be As Effective as In-Person Care for Psoriasishttps://practicaldermatology.com/news/online-care-may-be-as-effective-as-in-person-care-for-psoriasis/2457574/Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic skin diseases need ongoing care, and depending on where they live, their access to de
- EPI Acquires Rights to Cloderm Cream from Promius Pharmahttps://practicaldermatology.com/news/epi-acquires/2457576/EPI Health has acquired the rights rights to Cloder
- Allergan's New Campaign Urges Consumers to Just Juvéderm Ithttps://practicaldermatology.com/news/allergans-new-campaign-urges-consumers-to-just-juvderm-it/2457581/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- LEO Science & Tech Hub and Epicore Biosystems to Explore Wearable Skin Sensors to Improve Dermatologic Treatment Regimenshttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-to-explore-wearable-skin-sensors-to-improve-dermatologic-treatment-regimens/2457583/LEO Science & Tech Hub has established a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions. The initial project will inc
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://practicaldermatology.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2457597/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Experts Call for Improved Identification of "High Burden" Rosacea Patients in Everyday Practicehttps://practicaldermatology.com/news/experts-call-for-improved-identification-of-high-burden-rosacea-patients-in-everyday-practice/2457605/Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report called Rosacea: Beyond the visible, assists healthcare professionals in identifying the common char
- Almirall and Evotec Form Dermatology Research Collaborationhttps://practicaldermatology.com/news/almirall-and-evotec-form-dermatology-research-collaboration/2457607/Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The two companies have for